http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm345928.htm?source=govdelivery
"....
Nicotine-Containing Products
FDA has issued a citizen petition response and a Notice of Findings related to over-the-counter (OTC) nicotine replacement therapy (NRT) products, which are currently approved as aids to smoking cessation.
Citizen Petition Response
In January 2008, The State of New York's Commissioner of Health submitted a citizen petition to the Agency asking FDA to take various actions regarding the regulation of OTC NRT drug products. In February 2010, the University of Maryland School of Law submitted a petition raising similar issues on behalf of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. We received a third petition in August 2010, from four not-for-profit public health organizations: the American Cancer Society Cancer Action Network, the American Lung Association, the Campaign for Tobacco-Free Kids, and the American Legacy Foundation. These three petitions raise many common issues, so FDA issued a combined response granting and denying the various requests made in the petitions.
Notice of Findings
Each of the citizen petitions described above requested changes to approved drug product labeling for OTC NRT products. Because changes to the labeling of OTC NRT products must be supported by submissions from product sponsors to the appropriate New Drug Applications, FDA was unable to make the requested labeling changes through the citizen petition process. The Agency has, however, conducted its own review of the available literature and data on the safety of OTC NRT products. Based on that review, we have concluded that certain statements set forth in the approved labeling of OTC NRT products, including statements related to duration of use and concomitant use with other nicotine-containing products, can be modified. FDA intends to allow the modification of these statements based on sponsor submissions as set forth in a Notice of Findings.
Product sponsors may contact CDER's Division of Nonprescription Clinical Evaluation for samples of what the new labeling would look like with the changes supported by the Notice of Findings.
Contact:
Doris J. Bates, Ph.D.
Center for Drug Evaluation and Research
Food and Drug Administration ...."
_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network
No comments:
Post a Comment